NOV 05, 2018 10:00 AM PST

Drug Combination Halts The Progression of Fibrosis

WRITTEN BY: Nouran Amin

After seven years of research, scientists at Anglia Ruskin University, University College London and KU Leuven—developed a drug combination that holds a great deal of potential to halt the progression of Fibrosis.

Credit: Nordic Life Science

 

Initially, the researchers created a model that tests 21 different drugs to treat a disease in men called Peyronie's Disease. When tested on cells and animal models, they found that combining phosphodiesterase type 5 inhibitors (PDE5i) such as vardenafil (Levitra), sildenafil (Viagra) or tadalafil (Cialis) with selective estrogen receptor modulators (SERM) such as tamoxifen or raloxifene—treated fibrosis that causes Peyronie's Disease. Essentially, halting the progression.

 

"The principle of fibrosis is what causes Peyronie's Disease and so this is an important breakthrough. Although we do not believe this particular drug combination will be able to reverse the fibrotic process, it has the potential to treat all fibrotic diseases and halt progression,” says lead author Professor Selim Cellek, of Anglia Ruskin University. "This is an extremely exciting development and one that has taken several years of hard work. Fibrosis is a very serious condition that, when it affects a major organ, can be fatal.”

 

According to the study published in the journal European Urology, Fibrosis is known to cause half of all deaths. Responsible for conditions like cirrhosis of the liver, kidney, lung and heart—fibrosis occurs when damage causes a type of cell, called fibroblast, to convert itself into another type of cell called myofibroblast for the purpose of wound healing.

Image Credit: Promedior

After healing, the tissue that was previously damaged will return to its normal structure. However, in some cases that is not the case because the cells responsible, the myofibroblasts, will go out of control and 'overheal' the wound—causing scar tissue that holds no biological function.

 

Since scar tissue is dead tissue, its presence on major organs like the kidney, lungs, liver or heart, it is a serious tissue and estimated by the United States government cause 45% of all deaths. Developing a drug that can treat such an issue could save many lives. "To our knowledge, this is the first study of its kind to show a synergy between these two types of drugs. We look forward to taking this novel combination to clinical trials in the near future,” states Cellek.

Source: European Urology, Science Daily

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
NOV 26, 2020
Cardiology
Possible Cardioprotective Effects of the Diabetes Drug Empagliflozin
NOV 26, 2020
Possible Cardioprotective Effects of the Diabetes Drug Empagliflozin
Cardiovascular disease and diabetes are often associated with each other, as many issues caused by diabetes promote hear ...
NOV 26, 2020
Cannabis Sciences
Women More Likely than Men to Swap Prescription Medication for Cannabis
NOV 26, 2020
Women More Likely than Men to Swap Prescription Medication for Cannabis
The stigma around cannabis usage is fading as cannabis laws become increasingly lax. Now, researchers from DePaul Univer ...
DEC 17, 2020
Drug Discovery & Development
Molecular Mechanism Behind Ketamine for Depression Discovered
DEC 17, 2020
Molecular Mechanism Behind Ketamine for Depression Discovered
Over 30% of people with major depressive disorder are resistant to serotonin reuptake inhibitors (SSRI's), the curre ...
DEC 25, 2020
Drug Discovery & Development
Why Some Cancer Cells Are Drug Resistant?
DEC 25, 2020
Why Some Cancer Cells Are Drug Resistant?
Cancer is one of the most prominent diseases in the world. It takes many lives every year and treatment likely faces dru ...
JAN 18, 2021
Immunology
Arthritis Drug Approved for Critically Ill COVID Patients
JAN 18, 2021
Arthritis Drug Approved for Critically Ill COVID Patients
Critically ill COVID patients in the U.K. may receive an arthritis drug after a study showed that treatment lowered mort ...
JAN 25, 2021
Cancer
Combining Radiotherapy and Immunotherapy in Liver Cancer
JAN 25, 2021
Combining Radiotherapy and Immunotherapy in Liver Cancer
The dream of a magic bullet drug plagues the mind of scientists, doctors, and patients. The truth is some diseases are j ...
Loading Comments...